18KIT
Dexcom G7 is now available in
the US, Germany, the UK, Ireland,
Austria, Hong Kong, New Zealand
and South Africa with additional
launches planned throughout 2023.
Feedback from initial Dexcom G7
users has been extremely positive,
with consistent praise for the 60%
smaller wearable, shortest warmup
period on the market and more
engaging and consumer-friendly
mobile app. In addition, 97% of initial
users surveyed found Dexcom G7
easy to use.
Significant
improvements
For people with diabetes treated with
insulin, Dexcom rtCGM is associated
with significant improvements over
patients' lifetimes and is likely to be
cost-saving to the NHS, a study says.
"Cost-Effectiveness of a RealTime Continuous
Glucose Monitoring
System Versus Self-Monitoring of
Blood Glucose in People with Type
2 Diabetes on Insulin Therapy in the
UK" was published in in Diabetes
Therapy, and stated, "Dexcom rtCGM
has enormous value, not only in
how it can improve quality of life
for people managing diabetes, but
also because it is likely to save the
NHS money."
In the study, a long-term health
economic analysis was determined
using the IQVIA CORE Diabetes
Model - which allows the calculation
of long-term outcomes, based on
the best data currently available - to
establish the cost-effectiveness for
funding Dexcom rtCGM technology
versus testing with finger pricks. The
analysis suggests that, compared to
finger pricks, use of rtCGM results in
significant improvements in baseline
glycated haemoglobin (HbA1c), as
well as reductions in long-term
diabetes-related complications and
emergency department visits1.
This analysis follows previous
research that proved Dexcom
technology to be cost-effective for
people with type 1 diabetes in 2020 in
the UK.
Ben Byrne, country director of UK
& Ireland at Dexcom, "As healthcare
technology, such as Dexcom's
rtCGM Systems, continue to evolve,
policymakers have a tremendous
opportunity to re-evaluate the
standard of care offered to the
diabetes community. Dexcom rtCGM
has enormous value, not only in
how it can improve quality of life
for people managing diabetes, but
also because it is likely to save the
NHS money. Our recent analysis
clearly adds to the evidence that
rtCGM is not only a highly costeffective
intervention for people
with diabetes compared to finger
pricking but is also likely to be cost
saving. Given these findings, and with
diabetes being so costly to healthcare
providers in the UK, we need to take
action and mandate more effective
glucose monitoring consistently
across the NHS and in the UK."
For more information, read the
study HERE.
Side by Side - Dexcom G6 and G7